Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE

Pfizer shares top-line data from pivotal study of pentavalent meningococcal vaccine in adolescents

By Brian Buntz | September 15, 2022

PfizerAiming to extend its vaccine empire, Pfizer (NYSE:PFE) has announced that its meningococcal vaccine (MenABCWY) candidate met primary and secondary endpoints in a Phase 3 study.

The NCT04440163 study tested the vaccine in healthy individuals between the ages of 10 and 25.

The vaccine candidate demonstrated non-inferiority to the licensed vaccines Trumenba and Menveo for the five meningococcal serogroups that cause the most invasive meningococcal disease: serogroups A, B, C, W and Y.

If approved, the vaccine could be the first to protect against the five meningococcal serogroups.

Pfizer plans on filing for U.S. approval in the fourth quarter of 2022. The company also plans to seek authorization for the vaccine in other regions.

At present, FDA has approved discrete MenACWY and MenB vaccines.

The NCT04440163 study randomly assigned participants to receive two doses of MenABCWY or two doses of Trumenba plus one dose of Menveo. Pfizer is the developer of Trumenba, while Menveo is from GSK (NYSE:GSK).

The study was active-controlled and observer-blinded. A total of 78 study locations took part in the trial.

Pfizer said the vaccine was well-tolerated with a similar safety profile to licensed vaccines.

“A pentavalent vaccine has the potential to help simplify what is currently a complex meningococcal vaccination schedule in the U.S. and improve vaccine coverage,” said Annaliesa Anderson, senior vice president and chief scientific officer, vaccine research and development at Pfizer. “Our goal is to help ensure as many adolescents and young adults as possible are protected against this devastating disease.”

Pfizer estimates that there are roughly 52 million adolescents and young adults in the age range for meningococcal vaccination based on CDC guidance.

PFE shares ticked down half a point to $45.94.


Filed Under: Infectious Disease
Tagged With: meningococcal vaccine
 

About The Author

Brian Buntz

As the pharma and biotech editor at WTWH Media, Brian has almost two decades of experience in B2B media, with a focus on healthcare and technology. While he has long maintained a keen interest in AI, more recently Brian has made making data analysis a central focus, and is exploring tools ranging from NLP and clustering to predictive analytics.

Throughout his 18-year tenure, Brian has covered an array of life science topics, including clinical trials, medical devices, and drug discovery and development. Prior to WTWH, he held the title of content director at Informa, where he focused on topics such as connected devices, cybersecurity, AI and Industry 4.0. A dedicated decade at UBM saw Brian providing in-depth coverage of the medical device sector. Engage with Brian on LinkedIn or drop him an email at bbuntz@wtwhmedia.com.

Related Articles Read More >

Coronavirus Covid-19 background - 3d rendering
Pregnancy associated with less long COVID: Researchers call for studies on protective biology
How technology advances are helping scientists unlock the mysteries of zoonotic diseases
Novel coronovirus
Advances in next generation vaccine development for SARS-CoV-2
Gay couple enjoying life together
World AIDS Day Summit & Celebration slated for early December
“ddd
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest news and trends happening now in the drug discovery and development industry.

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
Drug Discovery and Development
  • MassDevice
  • DeviceTalks
  • Medtech100 Index
  • Medical Design Sourcing
  • Medical Design & Outsourcing
  • Medical Tubing + Extrusion
  • Subscribe to our E-Newsletter
  • Contact Us
  • About Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2025 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Women in Pharma and Biotech
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • Resources
    • Video features
    • Podcast
    • Webinars
  • Pharma 50
    • 2025 Pharma 50
    • 2024 Pharma 50
    • 2023 Pharma 50
    • 2022 Pharma 50
    • 2021 Pharma 50
  • Advertise
  • SUBSCRIBE